PIM1

PIM Kinases have emerged as promising therapeutic targets for cancer treatment, offering new avenues for the development of targeted therapies aimed at combating tumor growth and progression. As key regulators of cell survival and proliferation, dysregulated PIM kinase signaling plays a critical role in oncogenesis, making them attractive targets for intervention in various cancer types. The exploration of PIM kinases as therapeutic targets represents a significant advancement in the field of precision medicine, with the potential to improve patient outcomes and overcome resistance to conventional cancer treatments. PIM kinases belong to a family of serine/threonine protein kinases comprising thee isoforms – PIM-1, PIM-2 and PIM-3. These kinases are involved in multiple signaling pathways implicated in cancer development, and progression, including cell cycle regulation, apoptosis and cellular metabolism. Aberrant activation of PIM kinases have been observed in a wide range of cancer types where they promote tumor cell survival, proliferation and resistance to apoptosis. Additionally, PIM kinases have been associated with poor prognosis and treatment resistance in cancer patients, underscoring their significant as potential therapeutic targets. Download Insight: The dysregulated expression and activity of PIM kinases in cancer cells make them attractive targets for therapeutic interventions. By selectively inhibiting PIM kinase activity, it is possible to disrupt key signaling pathways involved in tumor growth and survival, thereby inhibiting cancer cells proliferation and inducing cell death. Moreover, targeting PIM kinases offers the potential to overcome resistance to conventional cancer therapies, such as chemotherapy and targeted therapies, by targeting alternative survival pathways utilized by cancer cells. Preclinical studies have provided compelling evidence supporting the efficacy of PIM kinase inhibitors like AZD1208, SGI-1776 and LGH447 in inhibiting tumor growth and enhancing the sensitivity of cancer cells to chemotherapy and targeted therapies. In various cancer models, including leukemia, lymphoma, myeloma and prostate cancer, PIM kinase inhibitors have demonstrated potent anticancer activity and favorable safety pro These promising preclinical findings have paved the way for the evaluation in PIM kinase inhibitors in clinical trials. Clinical trials evaluating the safety and efficacy of PIM kinase inhibitors in cancer patients are underway, with encouraging preliminary findings reported in some studies. While challenges, such as dose-limiting toxicities and patient selection criteria need to be addressed, early clinical data suggests that PIM kinase inhibitors have the potential to be valuable addition to cancer treatment repertoire. Continued research efforts are focused on optimizing dosing regiments, identifying predictive biomarkers, and exploring combination therapies to maximize the therapeutic benefits of PIM kinase targeting therapies. The global market of PIM kinase targeted therapies have also witnessed some collaborations and license agreement coming to light, presenting the determination of researchers to bring these therapies into the clinical. Examples include the license agreement that Inflection Biosciences signed with AUM Biosciences to conduct the development of IBL-302, also known as AUM302, a first-in-class triple inhibitor of pan-PIM, pan-PI3K and mTOR kinases, presently in IND-enabling trials for neuroblastoma and cancers with PI3KCA mutations. Additionally, AUM302 was granted the Rare Pediatric Disease Designation from the FDA in January 2023 for the treatment of neuroblastoma, which came right after the agency designated it as an orphan drug for the same indication in November 2022. These designations signify recognition of its anticancer activities in neuroblastoma, presenting it as a promising clinical candidate to treat this rare cancer type. Looking into the future, the prospects of PIM kinase targeted therapies market for cancer looks promising, with ongoing research aimed at refining treatment strategies and expanding the therapeutic range. Advances in drug discovery technologies are facilitating the development of next-generation PIM kinase inhibitors with improved potency, selectivity and pharmacokinetic properties. Additionally, the identification of biomarkers predictive of response to PIM kinase inhibitors may enable more personalized treatment schedules, enhancing clinical outcomes and minimizing adverse effects. Furthermore, exploring the potential of combination therapies involving PIM Kinase inhibitors with other targeted agents, immunotherapies, conventional chemotherapy or radiation therapy holds promise for overcoming resistance mechanisms and improving treatment efficacy. Collaborative efforts between universities, hospitals and cancer research centers will be essential to advance the clinical development of PIM kinase inhibitors. In conclusion, PIM kinase targeted therapies represent attractive therapeutic targets for cancer treatment, offering the potential to disrupt key cancer signaling processes. Preclinical and early clinical data support the efficacy of PIM kinase inhibitors in inhibiting tumor growth and enhancing treatment response in various cancer types, primarily hematological cancers. With research underway for optimizing the dosing and treatment strategies, PIM kinase targeted therapies are poised to transform the landscape of cancer treatment.

AMERICAN FORK, Utah, May 1, 2024 /PRNewswire/ -- Biolexis Therapeutics, Inc. a clinical-stage AI-driven biopharmaceutical company, today announced it will present a late-breaking poster at the 2024 American Association of Immunologists (AAI), taking place May 3-7, 2024, in Chicago, IL. The conference brings together the top immunology experts for in-depth discussions exploring a wide array of topics, highlighting the latest groundbreaking discoveries in the field. Biolexis' scientific team will be presenting pre-clinical data demonstrating the efficacy of the company's novel PIM1-inhibitor, BLX-0631. AAI poster presentation details are below: Title: "Development of highly selective, potent, orally available PIM1 inhibitor BLX-0631 shows a therapeutics potential in Systemic Lupus Erythematosus (SLE) models" Session Title: Late-Breaking: Therapeutic Approaches to Autoimmunity (PM) Session Date and Time: Monday May 6, 2024, 2:15 PM - 3:30 PM Location: Exhibit Hall F1 Poster Board Number: B900 Abstract ID: 6301 More information can be found on the AAI meeting website. About Biolexis Therapeutics, Inc. Biolexis Therapeutics is a privately held clinical-stage biopharmaceutical company dedicated to developing small molecules targeting cancers, metabolic, neurodegenerative, auto-immune, and inflammatory diseases. Biolexis rapidly discovers and develops novel clinical candidates with unprecedented speed and accuracy through their proprietary MolecuLern™ AI-enabled drug discovery process. For more information, please visit SOURCE Biolexis Therapeutics Inc

AMERICAN FORK, Utah, April 1, 2024 /PRNewswire/ -- Biolexis Therapeutics, Inc. a clinical-stage biopharmaceutical company with a novel AI-assisted drug discovery platform technology, today announced it will present five posters at the 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA. AACR poster presentation details are below: Title: "Discovery of an oral, potent, and selective CDK9 molecular glue degrader SLX-3065 active in aggressive variant prostate cancers (AVPC)" Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2 Session Date and Time: Monday Apr 8, 2024 1:30 PM - 5:00 PM Location: Poster Section 52 Poster Board Number: 7 Abstract Presentation Number: LB161 Presenter: Chenyu Lin Title: "BLX-3030, a potent, selective, orally available small molecule CDK9 inhibitor for aggressive variant prostate cancers" Session Category: Experimental and Molecular Therapeutics Session Title: New Compounds and Drug Targets Session Date and Time: Tuesday Apr 9, 2024 9:00 AM - 12:30 PM Location: Poster Section 27 Poster Board Number: 2 Abstract Presentation Number: 4649 Presenter: Zhaoliang Li Title: "Development of highly selective, potent, orally available PIM1 inhibitor BLX0631 shows a therapeutics potential in multiple myeloma models" Session Category: Experimental and Molecular Therapeutics Session Title: HDAC and Methyltransferase Inhibitors Session Date and Time: Tuesday Apr 9, 2024 9:00 AM - 12:30 PM Location: Poster Section 24 Poster Board Number: 9 Abstract Presentation Number: 4587 Presenter: Kyle Medley Title: "Identification of a novel and selective Transglutaminase 2 (TGM2) inhibitors modulate tumor microenvironment in Glioblastoma" Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 4 Session Date and Time: Wednesday Apr 10, 2024 9:00 AM - 12:30 PM Location: Poster Section 54 Poster Board Number: 20 Abstract Presentation Number: LB444 Presenter: Hariprasad Vankayalapati Biolexis & TGen Collaboration Title: "Development of a novel ATP-competitive CDK9 inhibitor for treatment of pancreatic cancer" Session Category: Experimental and Molecular Therapeutics Session Title: Novel Biologic Therapies and Therapeutics Targets Session Date and Time: Tuesday Apr 9, 2024 1:30 PM – 5.00 PM Location: Poster Section 27 Poster Board Number: 5 Abstract Presentation Number: 5957 Presenter: Yesenia Barrera-Millan & Haiyong Han More information can be found on the AACR meeting website. About Biolexis Therapeutics, Inc. Biolexis Therapeutics is a privately held clinical-stage biopharmaceutical company dedicated to developing small molecules targeting cancers, metabolic, neurodegenerative, auto-immune, and inflammatory diseases. Biolexis rapidly discovers and develops novel clinical candidates with unprecedented speed and accuracy through their proprietary MolecuLern AI-enabled drug discovery process. For more information, please visit . SOURCE Biolexis Therapeutics Inc